Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs TG Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This chart provides a fascinating comparison between Lantheus Holdings, Inc. and TG Therapeutics, Inc. from 2014 to 2023. Over this period, Lantheus Holdings has seen a steady increase in SG&A expenses, peaking at approximately 267 million in 2023, a 270% increase from 2014. In contrast, TG Therapeutics experienced a more volatile trajectory, with a significant spike in 2020, reaching around 122 million, before stabilizing in subsequent years. This divergence highlights the differing strategic approaches of these companies in managing operational costs. Lantheus's consistent growth in expenses suggests a stable expansion strategy, while TG Therapeutics' fluctuations may indicate adaptive responses to market challenges. Understanding these trends offers valuable insights into the financial health and strategic priorities of these industry players.